rifaprim and Acute-Disease

rifaprim has been researched along with Acute-Disease* in 2 studies

Other Studies

2 other study(ies) available for rifaprim and Acute-Disease

Article	Year
[The efficacy of using the Soviet antibiotic rifamethoprim in treating acute bacterial pneumonias and chronic bronchitis]. Terapevticheskii arkhiv, 1992, Volume: 64, Issue:3 Rifametoprim (600 mg/day) was given to 64 patients with acute bacterial pneumonia, acute bronchitis and exacerbation of chronic bronchitis. 201 (83.4%) out of 241 isolates were sensitive to the action of the antibiotic. The treatment turned out effective in 84.4% of cases. Topics: Acute Disease; Bacteria; Bronchitis; Capsules; Chronic Disease; Drug Combinations; Drug Evaluation; Humans; Microbial Sensitivity Tests; Pneumonia; Remission Induction; Rifampin; Sputum; Trimethoprim	1992
[Use of rifamethoprim in acute and chronic respiratory tract diseases]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1992, Volume: 37, Issue:1 Rifamethoprim is a new formulation containing rifampicin and trimethoprim. Its efficacy was studied in the treatment of a group of patients with various nonspecific diseases of the lungs. It was shown to be highly active against a broad spectrum of pathogens. With inclusion of trimethoprim to the formulation it appeared possible to markedly lower the bacterial ability to develop resistance to rifampicin, which solved the problem of long-term antibiotic use. The unique pharmacokinetic properties of rifampicin such as its capacity to penetrating into the sputum, lung tissues and cells make rifamethoprim be the drug of optimal choice in the treatment of respiratory diseases. Topics: Acute Disease; Anti-Bacterial Agents; Bronchial Diseases; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Humans; Lung Diseases; Rifampin; Trimethoprim	1992

Article

Year

[The efficacy of using the Soviet antibiotic rifamethoprim in treating acute bacterial pneumonias and chronic bronchitis].

Terapevticheskii arkhiv, 1992, Volume: 64, Issue:3

Rifametoprim (600 mg/day) was given to 64 patients with acute bacterial pneumonia, acute bronchitis and exacerbation of chronic bronchitis. 201 (83.4%) out of 241 isolates were sensitive to the action of the antibiotic. The treatment turned out effective in 84.4% of cases.

Topics: Acute Disease; Bacteria; Bronchitis; Capsules; Chronic Disease; Drug Combinations; Drug Evaluation; Humans; Microbial Sensitivity Tests; Pneumonia; Remission Induction; Rifampin; Sputum; Trimethoprim

1992

[Use of rifamethoprim in acute and chronic respiratory tract diseases].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1992, Volume: 37, Issue:1

Rifamethoprim is a new formulation containing rifampicin and trimethoprim. Its efficacy was studied in the treatment of a group of patients with various nonspecific diseases of the lungs. It was shown to be highly active against a broad spectrum of pathogens. With inclusion of trimethoprim to the formulation it appeared possible to markedly lower the bacterial ability to develop resistance to rifampicin, which solved the problem of long-term antibiotic use. The unique pharmacokinetic properties of rifampicin such as its capacity to penetrating into the sputum, lung tissues and cells make rifamethoprim be the drug of optimal choice in the treatment of respiratory diseases.

Topics: Acute Disease; Anti-Bacterial Agents; Bronchial Diseases; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Humans; Lung Diseases; Rifampin; Trimethoprim

1992